inSoma Bio Analysis: $3M Raised
What is inSoma Bio?
inSoma Bio develops protein-based biomaterials for reconstructive plastic surgery. Its Fractomer Biomatrix starts as a liquid at room temperature and becomes a porous scaffold at body temperature. The company targets surgeons performing breast and facial reconstruction using a patient’s own tissue instead of synthetic implants and fillers.
Location
Durham, North Carolina 27701, United States
Employees
1-10
Founded
2018
Revenue
<$5M
Product Features & Capabilities
- Fractomer Biomatrix, bio-inspired solutions for reconstructive plastic surgery, utilizes a person's own tissue instead of synthetic implants, provides support, shape, and biointegration for co-injected cells or tissues, features a thermal switch activated at body temperature, designed at the genetic level without harvesting natural tissue.
How much inSoma Bio raised
s: - $2.5 million
November 1st, 2023Lead Investor: Not specified
Who are the founders of inSoma Bio
SR
AC
Ashutosh Chilkoti
Chairman
Market Focus
inSoma Bio primarily focuses on the medical industry, specifically in the field of reconstructive plastic surgery. They develop bio-inspired solutions that utilize a person's own tissue instead of synthetic implants and fillers.
Business Model
Revenue generated through sales of Fractomer products to medical institutions and surgeons.
Competitors Overview
inSoma Bio operates in the reconstructive plastic surgery market, focusing on bio-inspired solutions that utilize a patient's own tissue instead of synthetic implants. Its main competitors include:
-
Silk Biomed: This company specializes in neuroregenerative biomaterials, which may offer advantages in nerve repair and regeneration compared to traditional methods. Their focus on silk-based materials provides a unique biocompatibility profile.
-
Amber Implants: Known for manufacturing vertebral implants, Amber Implants emphasizes innovative healing components that can enhance recovery and integration with the body. Their patented technologies may provide specific advantages in dental and orthopedic applications.
-
Invicare: Although specific details about Invicare's offerings were not found, they are known to operate in the biomaterials space, potentially competing with inSoma Bio in terms of product applications and market reach.
Notable differences include inSoma Bio's unique approach of using a patient's own tissue, which may reduce the risk of rejection and complications associated with synthetic materials, setting it apart from competitors who may rely more heavily on synthetic implants.
Investors
- Duke Capital Partners (Houston)
- Duke Innovation and Entrepreneurship
- FemHealth Ventures
- MedBlue Incubator
- Wallace H.
- Y Combinator
- America's Seed Fund
- Oriza Ventures
- CAV Angels
- North Carolina Biotechnology Center
See something that needs updating? Suggest edits to this profile.